A dry macular degeneration diagnosis often comes with a frustrating question: Is there anything more I can do to protect the vision I still have?
For some patients, low-level light therapy (LLLT), also called photobiomodulation, may be another option to discuss with their eye doctor. This non-invasive treatment uses specific wavelengths of light to support retinal cell function and is intended for certain patients with dry age-related macular degeneration.
LLLT does not cure macular degeneration, and it is not appropriate for everyone. Understanding how the treatment works, who may qualify, and what to expect can help you have a more informed conversation about whether it belongs in your AMD care plan.
What Is Low-Level Light Therapy?
Low-level light therapy uses specific wavelengths of light to stimulate biological processes within retinal cells. The treatment is delivered through a specialized device without needles, incisions, or medication being placed inside the eye.
Photobiomodulation is designed to support the mitochondria, which are the structures within cells responsible for producing energy. By influencing mitochondrial activity, the treatment may help aging or stressed retinal cells function more efficiently and better manage oxidative and inflammatory stress.
Low-level light therapy is not a cure for macular degeneration. It is an emerging option intended to support retinal function in carefully selected patients.
How May LLLT Help Patients With Dry Macular Degeneration?
Dry age-related macular degeneration affects the macula, the central portion of the retina responsible for detailed vision. As the condition progresses, patients may have greater difficulty reading, recognizing faces, driving, or seeing fine details.
Clinical studies of photobiomodulation have reported promising findings in some patients, including modest improvements in visual acuity and other measures of visual function. Researchers have also studied its potential effects on drusen and other anatomical signs associated with dry AMD, although the clinical evidence continues to evolve.
The U.S. Food and Drug Administration has authorized a prescription photobiomodulation device for certain patients with dry AMD. However, this authorization applies to a defined group of patients based on factors such as visual acuity, drusen, and the location or stage of retinal changes. It does not mean that LLLT is appropriate for every person with macular degeneration.
Who May Be a Candidate for LLLT?
Determining candidacy begins with a comprehensive eye examination and detailed retinal evaluation. The doctor needs to confirm the type and stage of macular degeneration while ruling out conditions that may require a different approach.
The evaluation may consider:
- Whether the patient has dry or wet macular degeneration
- Current visual acuity
- The presence, size, and distribution of drusen
- Whether geographic atrophy is present and where it is located
- Other retinal or ocular health conditions
- Current medications, supplements, and treatment recommendations
- The patient’s overall health and visual goals
Patients with wet macular degeneration or certain advanced retinal changes may not qualify for this form of treatment. LLLT should only be considered after an eye doctor determines that the patient meets the appropriate clinical criteria.
What Happens During Photobiomodulation Treatment?
During treatment, the patient looks into a specialized device that delivers controlled wavelengths of light to the retina. No injections or surgical incisions are involved, and patients can generally return to their usual activities afterward unless their doctor provides different instructions.
Treatment is typically delivered as a scheduled series rather than a single visit. The number and timing of sessions depend on the device protocol, the patient’s retinal findings, and the doctor’s recommendations. Continued examinations and retinal imaging remain important for evaluating changes over time.
Can LLLT Cure Macular Degeneration?
No. Low-level light therapy cannot cure dry macular degeneration or restore retinal tissue that has already been permanently lost. It also cannot guarantee that the condition will stop progressing.
The goal is to support visual function and retinal health in patients who meet the treatment criteria. Individual responses vary, and some patients may not experience a noticeable improvement.
LLLT is usually considered as one part of a broader management plan that may include:
- Regular dilated eye examinations and retinal imaging
- At-home monitoring with an Amsler grid when recommended
- Nutritional supplements for qualifying patients
- A diet rich in leafy green vegetables and other nutrient-dense foods
- Smoking cessation
- Management of blood pressure and cardiovascular risk factors
- UV-protective eyewear
- Prompt evaluation of new distortion or sudden vision changes
Specialized treatment complements ongoing monitoring; it does not replace it.
Does Insurance Cover LLLT for Macular Degeneration?
Insurance coverage for LLLT varies by plan. Because photobiomodulation is still an emerging treatment, some insurers may permit billing for it, while many plans do not currently include it as a covered benefit.
Coverage may also depend on the patient’s diagnosis, clinical findings, policy language, provider network, and whether prior authorization is required. Even when an examination or retinal imaging is covered, the treatment sessions themselves may not be.
Before beginning treatment, patients may want to ask:
- Is photobiomodulation for dry AMD covered under my plan?
- Is prior authorization or documentation of medical necessity required?
- Are the evaluation, imaging, and treatment sessions covered separately?
- Do I have a deductible, coinsurance, or copayment?
- If treatment is not covered, what is the estimated self-pay cost?
A billing code does not automatically guarantee payment. Patients should request an estimate from the practice and confirm benefits directly with their insurance company because final coverage decisions are made by the insurer.
Is LLLT for AMD the Same as Light-Based Dry Eye Care?
No. Patients may encounter the term low level light therapy while researching both retinal care and dry eye treatment, but these applications target different parts of the eye and use different clinical protocols.
Someone searching for a dry eye optometrist may have irritation caused by an unstable tear film, eyelid inflammation, or blocked oil glands. These concerns require a separate ocular surface evaluation. Depending on the diagnosis, the care plan might include meibomian gland dysfunction treatment, blepharitis treatment, or another form of non surgical dry eye treatment.
Photobiomodulation for dry macular degeneration is directed toward the retina at the back of the eye. Patients should not assume that every light-based device or treatment protocol can be used interchangeably for dry eye and retinal disease.
Ask About LLLT in New Castle
For some patients with dry macular degeneration, low-level light therapy may provide another option to discuss alongside nutrition, lifestyle guidance, and regular retinal monitoring. The first step is a thorough examination to determine the type and stage of AMD and whether photobiomodulation may be clinically appropriate.
Contact Mohawk Eyecare to schedule a macular degeneration evaluation and discuss treatment eligibility, expected costs, and available insurance information. Visit the practice at 537 Mt Jackson Road in New Castle, PA, or call 724-667-2020.
Request an Eye Health Evaluation
Frequently Asked Questions
Is low-level light therapy approved for dry AMD?
The FDA has authorized a prescription photobiomodulation device for certain patients with dry age-related macular degeneration. Patients must meet specific clinical criteria, so an eye examination is necessary before treatment.
Does LLLT cure macular degeneration?
No. LLLT does not cure macular degeneration or guarantee improved vision. It is intended to support visual function in suitable patients as part of a broader management plan.
Is low-level light therapy invasive?
No. Photobiomodulation delivers light through a specialized device without injections or surgical incisions. Patients should still discuss the treatment experience, possible risks, and expected schedule with their doctor.
Will Medicare or private insurance cover LLLT?
Coverage varies among Medicare-related and private insurance plans. Some insurers may allow billing, while others consider the treatment non-covered. Patients should confirm their benefits and request a cost estimate before starting treatment.
Can LLLT replace eye vitamins or regular monitoring?
No. Patients should not stop supplements, monitoring, or other recommended care unless instructed by their eye doctor. LLLT is generally considered one component of an individualized AMD management plan.
Is LLLT used for wet macular degeneration?
Photobiomodulation for dry AMD is not a replacement for treatments used to manage wet macular degeneration. New distortion, missing areas of vision, or sudden changes should be evaluated promptly.